Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | PRKACA | P17612 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309011 | 0.72 | — | — | |
| SCHEMBL17112672 | 0.68 | — | — | |
| SCHEMBL1934832 | 0.68 | — | — | |
| SCHEMBL1723443 | 0.68 | — | — | |
| SCHEMBL1765938 | 0.68 | — | — | |
| SCHEMBL10017208 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL9534244 | 0.67 | TSHR (0.50) | TSHRCYP3A4BLMSCN9AMEN1 | |
| SCHEMBL29904250 | 0.63 | TSHR (0.42) | TSHRCYP3A4BLMSCN9AMEN1 | |
| SCHEMBL28351787 | 0.62 | TSHR (0.44) | TSHRCYP3A4BLM | |
| SCHEMBL28485762 | 0.59 | TSHR (0.46) | TSHRCYP3A4BLMCHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2665 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | claimed |
| CN-113329739-B | Antisense oligonucleotides targeted to SCN2A for the treatment of SCN1A encephalopathy | 罗贡股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| US-11939582-B2 | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies | ROGCON, INC. (US) | 2024-03-26 | — | — | US | claimed |
| CN-117715942-A | Enhanced targeting using antibody-oligonucleotide conjugates | 代码生物疗法公司 | 2024-03-15 | — | — | CN | claimed |
| EP-4314297-A1 | TARGETING ONCOGENTIC MUTATIONS WITH DUAL-CLEAVING ENDONUCLEASE | Specific Biologics Inc. (CA) | 2024-02-07 | — | — | EP | claimed |
| EP-4301859-A1 | ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Code Biotherapeutics, Inc. (US) | 2024-01-10 | — | — | EP | claimed |
| CN-117083385-A | Targeting oncogenic mutations with double-cleaving endonucleases | 特定生物制品公司 | 2023-11-17 | — | — | CN | claimed |
| WO-2023196944-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2023192885-A2 | METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | IONIS PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | claimed |
| US-20050053981-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | ISIS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | claimed |
| US-6825338-B2 | SELECTIVE FUNCTIONALIZATION OF OLIGONUCLEOTIDES WITH CONJUGATE GROUPS WITHOUT THE NEED FOR POST-SYNTHETIC LABELING; SOLID PHASE SYNTHESIS; DEBLOCKING AN ACID LABILE HYDROXYL GROUP AND REACTING WITH A PHOSPHORAMIDITE | ISIS PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | claimed |
| EP-1409731-A2 | METHODS OF MODULATING PHARMACOKINETICS OF OLIGONUCLEOTIDES | ISIS Pharmaceuticals, Inc. (US) | 2004-04-21 | — | — | EP | claimed |
| US-20040049022-A1 | Composition & methods for treatment and screening | NYCE JONATHAN W (US) | 2004-03-11 | — | — | US | claimed |
| WO-2004011613-A2 | COMPOSITION & METHODS FOR TREATMENT AND SCREENING | EPIGENESIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | claimed |
| EP-1379541-A1 | LABELED OLIGONUCLEOTIDES, METHODS FOR MAKING SAME, AND COMPOUNDS USEFUL THEREFOR | ISIS Pharmaceuticals, Inc. (US) | 2004-01-14 | — | — | EP | claimed |
| US-20030208061-A1 | Labeled oligonucleotides, methods for making same, and compounds useful therefor | ISIS PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | claimed |
| WO-2003004603-A2 | METHODS OF MODULATING PHARMACOKINETICS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | claimed |
| WO-2002079216-A1 | LABELED OLIGONUCLEOTIDES, METHODS FOR MAKING SAME, AND COMPOUNDS USEFUL THEREFOR | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | claimed |